Overview
Genesis Molecular AI uses artificial intelligence to speed up drug discovery for the pharmaceutical industry. It combines 3D spatial graph modeling with molecular simulations to generate and evaluate drug candidates and identify novel protein targets. The platform translates complex molecular data into actionable candidates and predicts how they bind to targets to help partners select promising therapies. It differentiates itself by integrating 3D spatial graph modeling with simulations to explore untapped chemical space and by focusing on B2B partnerships with pharma/biotech, with notable deals such as Eli Lilly and a $200M Series B led by Andreessen Horowitz; its goal is to accelerate partner drug discovery.
Work here?Claim your company
Simplify's take
What believers are saying
- May 2026 Incyte expansion delivered $120 million upfront, including $40 million equity.
- Incyte will share proprietary data and fund compute, improving Genesis model training.
- Genesis claims Pearl outperformed all cofolding models on OpenBind in October 2025.
What critics are saying
- Incyte owns exclusive commercialization rights, limiting Genesis’s downstream capture through 2026.
- OpenAI, Recursion, and Schrödinger intensify AI-drug-discovery competition for talent and partners.
- If Pearl and GEMS miss wet-lab success, Genesis becomes a services vendor.
What makes Genesis Molecular AI unique
- GEMS combines foundation models, physical simulation, and proprietary experimental data.
- Genesis secured Incyte’s exclusive 2025 and expanded 2026 collaboration rights.
- Sergey Edunov joined in December 2025 to scale foundation-model leadership.
Help us improve and share your feedback! Did you find this helpful?
